Pieris, Sanofi deal

Pieris received an undisclosed milestone payment from Sanofi under an expanded 2010 deal under which Pieris is using its Anticalin technology to discover and develop preclinical Anticalin candidates against undisclosed targets selected by Sanofi. Pieris said the milestone is related to the generation of sub-nanomolar Anticalins against multiple targets, forming the basis for an undisclosed multi-specific Anticalin program. Pieris said it is responsible for some, but not all, preclinical development under the deal. Sanofi directed questions on the deal to Pieris, which declined to disclose details. ...